Research shows that two FDA-approved bone-building medications, parathyroid hormone and abaloparatide, can repair jaw bone damage caused by type 2 diabetes in mice. According to Gram Research analysis of this 2026 study, these drugs increased bone formation without worsening bone loss in diabetic mice, leading to net bone gain. In healthy mice, the same medications increased both bone formation and loss with no net change. This discovery suggests these medications might eventually help diabetic patients preserve their teeth and improve dental implant success, though human studies are needed.
According to Gram Research analysis, scientists discovered that two FDA-approved bone-building medications can repair jaw bone damage caused by type 2 diabetes in mice. The study found that these drugs, parathyroid hormone (PTH) and abaloparatide, work differently in diabetic mice than in healthy mice. In diabetic animals, the medications increased bone formation without worsening bone loss, leading to net bone gain in the jaw. This discovery could eventually help diabetic patients keep their teeth longer and improve the success of dental implants by restoring the bone that supports them.
Key Statistics
A 2026 research study found that parathyroid hormone and abaloparatide increased jaw bone formation in diabetic mice without increasing bone loss, resulting in net bone gain, whereas these same medications produced no net change in healthy mice.
Research published in the International Journal of Oral Science in 2026 demonstrated that the bone-building effects of PTH and abaloparatide in diabetic mice involve suppression of sclerostin and Dickkopf-1 proteins and activation of Wnt signaling in periodontal ligament cells.
A 2026 study using genetically modified mice revealed that the PTH receptor in osteocytes is essential for the bone-building effects of these medications but not for bone loss effects, suggesting a dual mechanism of action.
The Quick Take
- What they studied: Whether two bone-building medications approved by the FDA could repair jaw bone damage caused by type 2 diabetes
- Who participated: Laboratory mice with type 2 diabetes induced by a high-fat diet, compared with healthy control mice
- Key finding: In diabetic mice, parathyroid hormone and abaloparatide increased bone formation without increasing bone loss, resulting in net bone gain in the jaw. In healthy mice, these same drugs increased both bone formation and loss, resulting in no net change.
- What it means for you: This research suggests that existing bone-building medications might eventually help diabetic patients preserve their teeth and improve dental implant success. However, this is early-stage research in mice, and human studies would be needed before these treatments could be used in dental care.
The Research Details
Researchers created a mouse model of type 2 diabetes using a high-fat diet combined with a chemical injection. They then treated both diabetic and healthy mice with two bone-building medications: parathyroid hormone (PTH) and abaloparatide (ABL). These drugs are already FDA-approved for treating osteoporosis in humans. The team measured how these medications affected bone formation and bone loss in the jaw bone, which is called alveolar bone. They also studied the molecular mechanisms, or the specific ways these drugs work at the cellular level, by examining special mice that lacked certain receptors for PTH signaling.
The researchers used advanced imaging and laboratory techniques to track changes in bone structure and to identify which cells and proteins were involved in the bone-building process. They looked at how the drugs affected osteocytes, which are mature bone cells that live inside bone tissue, and periodontal ligament cells, which are cells that help anchor teeth to bone. The study examined specific molecular pathways, including the Wnt signaling pathway, which is known to be important for bone formation.
This research approach is important because it reveals not just whether a treatment works, but how it works. By understanding the specific mechanisms, scientists can better predict whether these medications might be effective in humans and can identify which patients might benefit most. The use of genetically modified mice allowed researchers to pinpoint exactly which cellular receptors are responsible for the bone-building effects versus the bone-loss effects, which is crucial information for developing targeted therapies.
This study was published in a peer-reviewed scientific journal, which means other experts reviewed the work before publication. The research used established mouse models of diabetes and FDA-approved medications, lending credibility to the findings. However, this is laboratory research in mice, not human studies. Mouse studies often don’t translate directly to humans, so results should be considered preliminary. The study did not specify the exact number of mice used, which makes it harder to assess statistical power. The findings are promising but require validation in human clinical trials before any clinical applications.
What the Results Show
The most striking finding was that parathyroid hormone and abaloparatide had opposite effects in diabetic versus healthy mice. In healthy mice, these drugs stimulated bone formation but also increased bone loss, resulting in no net change in bone mass. This is consistent with how these medications work in the body generally: they activate bone remodeling, which includes both building new bone and breaking down old bone.
In diabetic mice, however, the same medications increased bone formation without increasing bone loss, leading to a net gain in jaw bone mass. This selective anabolic effect, meaning bone-building without increased bone loss, was the key discovery. The researchers found that this beneficial effect involved suppression of two proteins called sclerostin and Dickkopf-1 (Dkk-1), which normally inhibit bone formation. By reducing these inhibitory proteins, the medications activated the Wnt signaling pathway in periodontal ligament cells, which promoted bone formation.
Using specialized mice that lacked the PTH receptor specifically in osteocytes (mature bone cells), the researchers demonstrated that this receptor is essential for the bone-building effects of these medications. Importantly, the PTH receptor in osteocytes was not responsible for the bone-loss-promoting effects, suggesting that the bone loss occurs through a different mechanism. This finding is significant because it suggests that future therapies could potentially target only the bone-building pathway while avoiding unwanted bone loss.
The research revealed that the molecular mechanisms differ between diabetic and healthy states. In healthy mice, the medications activate bone remodeling broadly, affecting both bone formation and bone loss equally. In diabetic mice, the same medications preferentially activate bone formation pathways. This suggests that diabetes creates a different metabolic environment in bone tissue that allows these medications to work more selectively. The study also identified that periodontal ligament cells, which are the cells that attach teeth to bone, play an important role in the bone-building response through Wnt signaling activation.
Previous research has shown that type 2 diabetes damages bone quality and increases fracture risk despite sometimes increasing bone density, a paradox called diabetic bone disease. This study builds on that knowledge by showing that bone-building medications can work differently in diabetic bone tissue. The findings align with existing research showing that the Wnt signaling pathway is crucial for bone formation and that sclerostin and Dkk-1 are important regulators of this pathway. However, this is the first study to demonstrate that FDA-approved bone anabolic agents can selectively promote bone formation in diabetic jaw bone without worsening bone loss, which is a novel finding specific to oral bone and diabetes.
This research was conducted in mice, not humans, so results may not directly translate to human patients. The study did not report the specific number of animals used, making it difficult to assess the statistical power and reliability of the findings. The research used a specific type of diabetes model (high-fat diet plus chemical injection), which may not perfectly replicate all aspects of human type 2 diabetes. The study examined only jaw bone, so it’s unclear whether these results would apply to other bones in the body. Long-term effects were not studied, so it’s unknown whether the bone-building benefits persist over time or whether side effects might emerge. Finally, this is basic research demonstrating proof of concept, not a clinical trial, so safety and efficacy in humans remain to be determined.
The Bottom Line
Based on this research, there are no current recommendations for using these medications specifically for diabetic bone disease in humans. The findings are promising and suggest that future clinical trials in diabetic patients with tooth loss or those considering dental implants may be warranted. Patients with type 2 diabetes should continue following their dentist’s recommendations for oral care and their doctor’s recommendations for diabetes management. If you have type 2 diabetes and are concerned about bone health or tooth retention, discuss these concerns with your healthcare provider, but do not expect these medications to be prescribed for dental purposes until human clinical trials demonstrate safety and efficacy.
This research is most relevant to people with type 2 diabetes who are experiencing bone loss in the jaw or tooth loss, as well as those considering dental implants. It’s also important for dentists, endocrinologists (diabetes specialists), and oral surgeons who treat diabetic patients. Researchers developing new bone-building therapies should pay attention to these findings. People without diabetes or those with healthy bone density have less immediate reason to be concerned about these specific findings, though the research advances our general understanding of how bone-building medications work.
This is very early-stage research, so realistic timelines are long. If human clinical trials begin soon, it would typically take 5 to 10 years to complete Phase 1, 2, and 3 trials and obtain FDA approval for a new indication. Even if these medications are eventually approved for diabetic bone disease, benefits would likely take weeks to months to become apparent, similar to how osteoporosis medications work. Patients should not expect immediate results and should maintain realistic expectations about the pace of medical innovation.
Frequently Asked Questions
Can people with type 2 diabetes use parathyroid hormone or abaloparatide to rebuild jaw bone?
Not yet for this specific purpose. While a 2026 mouse study showed these FDA-approved medications can rebuild diabetic jaw bone, human clinical trials have not been conducted. These medications are currently approved only for osteoporosis treatment. Consult your doctor before considering any off-label use.
How does type 2 diabetes damage teeth and jaw bone?
Type 2 diabetes increases bone loss in the jaw while sometimes increasing bone density, creating weak bone that doesn’t support teeth well. High blood sugar impairs bone formation and increases bone breakdown, making teeth more likely to loosen or fall out over time.
What can diabetic patients do now to protect their teeth and jaw bone?
Maintain excellent blood sugar control through medication, diet, and exercise. Practice rigorous oral hygiene with twice-daily brushing and daily flossing. See your dentist every 3 to 6 months for professional cleanings and monitoring. Avoid smoking, which worsens bone loss.
When might these bone-building medications become available for diabetic dental patients?
This is early-stage research in mice. If human clinical trials begin soon, it would typically take 5 to 10 years for FDA approval of a new indication. Realistic timeline for clinical availability is at least 7 to 15 years away, if the research progresses successfully.
Do these bone-building medications work the same way in all bones?
This study examined only jaw bone in mice, so it’s unclear whether results apply to other bones. The diabetic state appears to change how these medications work, but more research is needed to understand effects on hip, spine, and other bones in diabetic patients.
Want to Apply This Research?
- Users with type 2 diabetes could track dental health metrics including tooth mobility, gum bleeding, and any tooth loss events. They could also log their diabetes management metrics like blood glucose levels and medication adherence, since good diabetes control may help preserve bone health.
- Users could set reminders for consistent oral hygiene practices, including twice-daily brushing, daily flossing, and regular dental checkups every 3 to 6 months. They could also track their diabetes management more closely, as better blood sugar control may help protect jaw bone and teeth.
- Over 6 to 12 months, users could track changes in tooth stability, gum health, and any new tooth loss. They should also monitor their diabetes control metrics and maintain regular dental imaging (X-rays) as recommended by their dentist to assess bone density changes over time.
This article summarizes early-stage laboratory research in mice and should not be interpreted as medical advice or as evidence that these treatments are safe or effective for human use. The medications discussed (parathyroid hormone and abaloparatide) are FDA-approved only for osteoporosis treatment in humans. Do not use these medications for any purpose other than their approved indication without explicit guidance from your physician. If you have type 2 diabetes and are concerned about bone health, tooth loss, or dental implants, consult with your dentist and endocrinologist. This research is preliminary and requires human clinical trials before any clinical applications can be established.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.